Head and Neck Cancer Infographic

Boehringer Ingelheim

Head and neck cancer is the term used to describe malignant tumours originating in the upper aerodigestive tract (UADT), including the oral cavity, larynx, pharynx and nasopharynx. The vast majority (90%) of Head and Neck cancers are Squamous Cell Carcinomas (HNSCC) arising from the epithelial membranes (mucus linings) of these regions¹, and as such they have many common features relating to their aetiology and classification.

Each year approximately 560,000 cases of head and neck cancer are diagnosed worldwide, and 300,000 patients die annually.² Incidence rates are more than twice as high in men than in women.³

Look at the infographic above to find out more.

1. Viviana P. Lutzky. D. J et al. 2008. Biomarkers for Cancers of the Head and Neck. Clinical Medicine: Ear, Nose and Throat, 1,5-15.

2. Boyle P et al. World Cancer Report 2008. International Agency for Research on Cancer.

3. American Cancer Society. Cancer Facts and Figures 2007 [Online]. Available at: http://www. Cancer. Org/downloads/STT/CancerFacts&FiguresTM.pdf [Last accessed April 2010].

Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.

† Not an official event of the 2012 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.

Boehringer Ingelheim on